Prognostic and Predictive Factors in Early-Stage Breast Cancer
Top Cited Papers
- 1 November 2004
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 9 (6), 606-616
- https://doi.org/10.1634/theoncologist.9-6-606
Abstract
Learning Objectives: After completing this course, the reader will be able to: Differentiate between prognostic and predictive factors in early-stage breast cancer. Identify prognostic factors used to determine the risk of recurrence and death for a patient with early-stage breast cancer. Identify predictive factors used to determine the optimal therapy for a patient with early-stage breast cancer. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com Breast cancer is the most common malignancy among American women. Due to increased screening, the majority of patients present with early-stage breast cancer. The Oxford Overview Analysis demonstrates that adjuvant hormonal therapy and polychemotherapy reduce the risk of recurrence and death from breast cancer. Adjuvant systemic therapy, however, has associated risks and it would be useful to be able to optimally select patients most likely to benefit. The purpose of adjuvant systemic therapy is to eradicate distant micrometastatic deposits. It is essential therefore to be able to estimate an individual patient's risk of harboring clinically silent micrometastatic disease using established prognostic factors. It is also beneficial to be able to select the optimal adjuvant therapy for an individual patient based on established predictive factors. It is standard practice to administer systemic therapy to all patients with lymph node-positive disease. However, there are clearly differences among node-positive women that may warrant a more aggressive therapeutic approach. Furthermore, there are many node-negative women who would also benefit from adjuvant systemic therapy. Prognostic factors therefore must be differentiated from predictive factors. A prognostic factor is any measurement available at the time of surgery that correlates with disease-free or overall survival in the absence of systemic adjuvant therapy and, as a result, is able to correlate with the natural history of the disease. In contrast, a predictive factor is any measurement associated with response to a given therapy. Some factors, such as hormone receptors and HER2/neu overexpression, are both prognostic and predictive.Keywords
This publication has 66 references indexed in Scilit:
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in CombinationJournal of Clinical Oncology, 2002
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Lymphatic Mapping and Sentinel Lymphadenectomy for Breast CancerAnnals of Surgery, 1994
- Conservative surgery and radiation therapy in black women with early stage breast cancer. Patterns of failure and analysis of outcomeCancer, 1992
- Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery, 1992
- Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failureThe Journal of Steroid Biochemistry and Molecular Biology, 1990
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Long term prognosis of women with breast cancer in New Zealand: study of survival to 30 years.BMJ, 1983
- Carcinoma of the breast in women under 30 years of age.A clinical and histopathological study of all cases reported as carcinoma to the Swedish Cancer Registry, 1958–1968Cancer, 1977